Cis Insulin Market By Product Type (Rapid-Acting Cis Insulin, Short-Acting Cis Insulin, Intermediate-Acting Cis Insulin, Long-Acting Cis Insulin, Ultra-Long-Acting Cis Insulin, Others), By Source (Human Recombinant Cis Insulin, Analog Cis Insulin), By Delivery Device (Vials & Syringes, Insulin Pens, Insulin Pumps, Others), By Route of Administration (Subcutaneous, Intravenous, Inhalation), By Application (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes, Others), and By End User (Hospitals, Specialty Diabetes Clinics, Ambulatory Surgical Centers (ASCs), Homecare Settings), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

Report Coverage:

By Product Type

• Rapid-Acting Cis Insulin
• Short-Acting Cis Insulin
• Intermediate-Acting Cis Insulin
• Long-Acting Cis Insulin
• Ultra-Long-Acting Cis Insulin
• Others

By Source

• Human Recombinant Cis Insulin
• Analog Cis Insulin

By Delivery Device

• Vials & Syringes
• Insulin Pens
• Insulin Pumps
• Others

By Route of Administration

• Subcutaneous
• Intravenous
• Inhalation

By Application

• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes
• Others

By End User

• Hospitals
• Specialty Diabetes Clinics
• Ambulatory Surgical Centers (ASCs)
• Homecare Settings

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Bristol-Myers Squibb
• Novartis
• Takeda Pharmaceuticals
• Boehringer Ingelheim
• Biocon
• Dongbao Enterprise Group
• Merck KGaA
• Oramed Pharmaceuticals
• Halozyme Therapeutics
• Wanbang Biopharma
• Xinbai Pharmaceutical
• Eli Lilly and Company
• Novo Nordisk
• Sanofi
• Merck & Co.